Gastromed Kralisz Romatowski Stachurska Sp. j. — Clinical Trial Site

8 Registered trials

2 Currently recruiting

Organisation

Gastromed Kralisz Romatowski Stachurska Sp. j.

Location

Bialystok, Poland

Identifier

ORG-100051116

Address

Ul. Wiosenna 12/1, 15-322, Poland

Departments

#PL10009:gastrology
Gastromed Kralisz Romatowski Stachurska Sp. j.
n/a
NA
NZOZ Specjalistyczne Centrum Gastrologii GASTROMED

Clinical trials at this site (8)

Search interface

A Study to Assess the Effectiveness and Safety of Induction Therapy with RO7790121 in Participants with Moderately to Severely Active Crohn'… Recruiting

2024-513054-30-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
A randomized, phase 3 multicenter study to confirm the clinical efficacy of linaprazan glurate compared to lansoprazole in participants with… Recruiting

2024-518714-31-00 Erosive esophagitis (EE) due to gastroesophageal reflux 5 2025-10-03
A Study to Assess the Effectiveness and Safety of RO7790121 for Induction Therapy in Participants with Moderately to Severely Active Ulcerat… Ended

2024-513015-27-00 Moderately to Severely Active Ulcerative Colitis (UC) 5 2025-01-09
A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease. Ended

2022-502789-26-01 Fibrostenotic Crohn’s Disease 4 2023-11-03
A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely… Ended

2023-504719-34-00 Moderate to Severly Active Ulcerative Colitis 5 2023-02-21
Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn's Disease Ended

2023-504740-33-00 Fistulizing perianal Crohn's Disease 5 2022-11-22
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504718-31-00 Moderately to Severely Active Ulcerative Colitis 10 2019-10-19
A randomized, phase 3 multicenter clinical trial to confirm the clinical efficacy and evaluate the safety of linaprazan glurate compared to … Ended

2025-522750-39-00 Erosive esophagitis (EE) due to gastroesophageal reflux 5